Drug Overview
FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination. FluMist QIV was approved for active immunization for the prevention of influenza in the US in February 2012 for subjects aged 2–49 years. FluMist QIV, branded as Fluenz Tetra in the EU, was then approved for use in subjects aged 2–18 years in December 2013 by the European Medicines Agency. Daiichi Sankyo submitted an application for regulatory approval in June 2016, and The author estimates the Japanese launch of FluMist QIV (MEDI3250) in the 2019/20 season.
Analyst Outlook
FluMist QIV (live-attenuated quadrivalent influenza vaccine; AstraZeneca/Daiichi Sankyo) is the only live-attenuated influenza vaccine
(LAIV) approved for seasonal influenza prophylaxis. Its ability to provide superior protection in infants aged 6–59 months had
previously placed the vaccine as the preferred option for children aged 2–8 years in the US (CDC, 2015).
FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination. FluMist QIV was approved for active immunization for the prevention of influenza in the US in February 2012 for subjects aged 2–49 years. FluMist QIV, branded as Fluenz Tetra in the EU, was then approved for use in subjects aged 2–18 years in December 2013 by the European Medicines Agency. Daiichi Sankyo submitted an application for regulatory approval in June 2016, and The author estimates the Japanese launch of FluMist QIV (MEDI3250) in the 2019/20 season.
Analyst Outlook
FluMist QIV (live-attenuated quadrivalent influenza vaccine; AstraZeneca/Daiichi Sankyo) is the only live-attenuated influenza vaccine
(LAIV) approved for seasonal influenza prophylaxis. Its ability to provide superior protection in infants aged 6–59 months had
previously placed the vaccine as the preferred option for children aged 2–8 years in the US (CDC, 2015).
Table of Contents
OVERVIEWDrug Overview
Product Profiles
FluMist QIV : Seasonal influenza vaccines
LIST OF TABLES
Table 1: FluMist QIV drug profile
Table 2: Approval history of FluMist QIV for seasonal influenza vaccination in the US and five major EU markets
Table 3: Late-phase trials of FluMist QIV for seasonal influenza vaccination
Table 4: FluMist QIV for seasonal influenza – SWOT analysis
